Page last updated: 2024-12-09

1-[[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]amino]-3-phenylthiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 1-[[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]amino]-3-phenylthiourea: A Look at Its Importance

The compound you've mentioned, 1-[[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]amino]-3-phenylthiourea, is a complex organic molecule with a rather long and descriptive chemical name. It's often referred to by its shorter name, **BTZT**, for simplicity.

**BTZT's Structure and Properties:**

BTZT is a derivative of thiourea, a molecule known for its ability to form strong hydrogen bonds. Its structure incorporates several important features:

* **Benzothiazole ring:** This aromatic ring is known for its fluorescence properties, making BTZT potentially useful in fluorescent probes or sensors.
* **Thiourea group:** This functional group is responsible for strong hydrogen bonding interactions with other molecules, potentially making BTZT a good candidate for binding to biomolecules like proteins or DNA.
* **Acetamide group:** This group adds further complexity to the molecule and potentially influences its biological activity.

**Why is BTZT Important for Research?**

BTZT and similar compounds have shown promise in various research areas, primarily due to their potential applications as:

* **Antimicrobial agents:** Studies have shown that BTZT exhibits antimicrobial activity against a range of bacteria and fungi. This could lead to the development of new antibiotic drugs.
* **Anti-cancer agents:** Some researchers have investigated the potential of BTZT and its analogs as anti-cancer agents, with promising results in inhibiting the growth of certain cancer cell lines.
* **Metal chelators:** BTZT's structure suggests it might act as a chelating agent, capable of binding to metal ions. This could have applications in areas like environmental remediation or metal-based drug delivery.
* **Fluorescent probes:** The benzothiazole ring in BTZT might be utilized to develop fluorescent probes for various biological applications, such as visualizing specific biomolecules or monitoring cellular processes.

**Key Considerations for Research:**

While BTZT shows promise, it is crucial to understand that its research is ongoing and needs further investigation.

* **Toxicity:** As with any new compound, thorough safety testing is essential to assess BTZT's potential toxicity and side effects before considering any therapeutic use.
* **Pharmacokinetic properties:** Further research is needed to understand how BTZT is absorbed, distributed, metabolized, and excreted within the body to optimize its delivery and effectiveness.
* **Mechanism of action:** Identifying the specific mechanisms by which BTZT exerts its antimicrobial, anti-cancer, or other effects is crucial to understand its potential applications and develop more targeted therapies.

**Conclusion:**

1-[[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]amino]-3-phenylthiourea (BTZT) is a complex organic molecule with a promising future in research. Its potential applications in various fields, including antimicrobial, anti-cancer, and fluorescent probe development, warrant further investigation and highlight the importance of continued research into this fascinating compound.

Cross-References

ID SourceID
PubMed CID1553611
CHEMBL ID1345374
CHEBI ID122001

Synonyms (13)

Synonym
MLS000591387
smr000219015
CHEBI:122001
2-[(1,3-benzothiazol-2-ylsulfanyl)acetyl]-n-phenylhydrazinecarbothioamide
STL071029
1-[[2-(1,3-benzothiazol-2-ylsulfanyl)acetyl]amino]-3-phenylthiourea
HMS2513G09
AKOS005641587
HMS3375G08
CHEMBL1345374
Q27210627
1-[[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]amino]-3-phenylthiourea
2-[(1,3-benzothiazol-2-ylthio)acetyl]-n-phenylhydrazinecarbothioamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzothiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency15.81140.140911.194039.8107AID2451
thioredoxin reductaseRattus norvegicus (Norway rat)Potency11.22020.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency0.70790.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency8.91250.011212.4002100.0000AID1030
PINK1Homo sapiens (human)Potency31.62282.818418.895944.6684AID624263
regulator of G-protein signaling 4Homo sapiens (human)Potency50.11870.531815.435837.6858AID504845
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.89130.28189.721235.4813AID2326
ParkinHomo sapiens (human)Potency31.62280.819914.830644.6684AID624263
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.54810.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency12.58930.001815.663839.8107AID894
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency2.73340.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency19.73470.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]